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IWeP3S1 Detection of gram-negative resistance to
amlnoglyc05ides with PhoenixTM 100 System
B. Turng,J. Hong, S. Wulff, S. O'Rourke, K. Fischbein
BD BiOllienas, Sparks, MD, Unittd Statts
Objectives: To evaluate the performance of the PhoenixTM 100 Auto-
mated Microbiology System (currently under development) in detecting
resistance to aminoglycosides in gram-negative bacilli.
Methods: A total of 210 isolates, including fresh clinical isolates (100
isolates) and a challenge set (110 strains) with various known resistance
mechanisms, were tested in parallel in a NCClS recommended Standard
Broth Microdilution (SBM) procedure and in the Phoenix System. Dou-
bling dilutions of six aminoglycosides (Amikacin, Gentamicin. lsepamycin,
Kanamycin, Netilmicin and Tobramycin) were prepared according to the
NCClS guidelines. Reference SBM panels were manually read after 16-20
h ofincubation at 35°C in ambient air. Phoenix panels were tested with an
inoculum concentration of5 x 105 cfulml. incubated and kinetically read by
the instrument every 20-min.
Results: Es..ential Agreement between the two procedures for the antimi-
crobial agents tested ranged from 91 to 97%. with no very major error
(VME) or major error, except Iscpamycin and Tobramycin (I strain with
VME). The average time to result. was 6 to 9 h for most enteric isolates and 9
to 13 h for other gram-negative bacilli.
Conclusions: The results of this evaluation indicate that the Phoenix system
can provide a rapid detection of aminoglycoside resistance among gram-
negative bacilli for clinical laboratories.
IWeP36I Novel streptomycin resistant mutants of salmonella
typhimurium isolated in an In Vitro kinetic model
I. Gustafsson
'
• D. 1. Andersson2, O. Cars'
'Dept. of Infectious Diseases, University Hospital Uppsala; lSwedish It,st.for
Infectious Disease Control, Solna, Swedm
Objectives: S. typhimllrium 1 T2 was used for selection of streptomycin
resistant sub-populations in an it' vitro kinetic model. Other models with
static concentrations does not reflect the potential selective properties of
fluctuating levels achieved during treatment.
Methods: Bacteria were exposed to two doses of streptomycin at lOx
respective 500 x MIC in an in vitro kinetic model. The elimination rate was
set to achieve MIC at 12 h for both dosing regimens and the second dose was
given at 12 h. Samples were withdrawn at different times during 24 hand
cultured on plates with O. 2, 50 and 500 x MIC ofstreptomycin. The .elccted
mutants were further investigated by PFGE, PCR and Southern hybridisa-
tion to identify the mutation sites.
Results: With two exposures of 500 X MIC maximal killing effect was
obtained after 24 h and no mutants were isolated. With 10 x MIC there was
no significant killing effect of the bacteria and regrowth occurred after 6 h.
Ten resistant clones with MIC values between 32 and > 1024 mgll were
chosen for further studies. One high-level resistant isolate contained a
previously described point mutation in the rpsL gene. The remaining isolates
had mutations at novel sites identified in the aadA, unc and litA genes.
Conclusions: An initial dose of 10 x MIC followed by decreasing concen-
trations selected for other types of streptomycin resistant mutants as
compared to previous studies using agar plate selection. The emergence of
these mutants was prevented by a higher dose.
IWeP37IResistance surveillance of greek Haemophilus
influenzae (H.I.) strains isolated from healthy carriers in 1997-
1998
1. Daskalaki, E. Mandaraka. K. Kanellakopoulou, H. Giamarellou
4th Department of Internal Medicine, Athens Medical School, Athens, Greece
Resistance surveillance of H.1. in Greece. derived mostly from specimens of
patients with chronic bronchitis and performed in 1988. revealed resistance
rates to Ampicillin 28.3%. to Cefaclor 2.7%. to Tetracycline 10.6%. and to
Trimethoprim/Sulfamethoxazole (TMP-SMZ) 5.3%. To extend our sur-
veillance follow-up, a study was organized in the winter 1998. Samples from
608 healthy individuals were obtained with naso-pharyngeal swabs: 189
from adults and 419 from children 3-7 years old. The rate ofisolation ofH.I.
was 5.8% for the adults and 36.5% for the children (11 and 153 isolates
re<p"crively). Socioeconomic classes differences were irrelevant to the rat.. of
nasopharyngeal carriage. 159 isolates were tested and MICs (jJ.g/ml) were
performed by a microdilution technique using HTM broth. Resistance to
Ampicillin (MIC > 2) was 13.2%, to Cefaclor (MIC > 16) 0.6%, to
Tetracycline (MIC > 4) 4.4%, to TMP/SMZ (MIC > 1/19) 13.83%. to
Clarithromycin (MIC > 16) 2.3% while MlCs90 were as follows: Ampi-
cillin < 2 (MIC50 < 12): Amoxicillin/Clav < 2/1; Ampicillin/Sulb < 11
0.5; Cefaclor < 4: Cefuroxime < I; Cefixime < 0.12; Ceftriaxone < 0.03:
Cefepime < 0.12; Imipenem < 0.5: Rifampin < 0.5; Tetracyclin < 0.5;
Chloramphenicol < 0.25: TMPISMZ < 2/38; Ciprofloxacin < 0.015;
Trovafloxacin < 0.03; Grepafloxacin < 0.03; Spartloxacin < 0.03; Clar-
ithromycin < 8. It is concluded that resistance rates of H.I. to classical
antimicrobial agents is decreasing. a fact probably attributed to the increased
use of newer macrolides in the community.
[WeP3i] Which is the appropriate technique to asses the
susceptibility of Staphylococcus aureus in dinicallaboratory1
(Aminoglycosides, MLSB group and Fluoroquinolones)
N. Sasca2, c.l. Sasca l , V. Laza-Stanca l , D. Tifreaz• A. Slavcovici2• D.
Cantina2, F. Sasca2
Infectiolls Diseases Hospital, Clinical Laboratory, Cilly-Napoca, Romania
Objectives: To asses the appropriate technique to test the MlSB, amino-
glycosides and quinolones resistance of staphylococci.
Methods: The susceptibility of 60 Staphylococcus aureus (SA) and 50
coagulase-negative staphylococci (CNS) strains belonging to 8 species
(biochemical identification by API-system Merieux) was tested in Muel-
ler-Hinton agar by disk diffusion, agar dilution and E-test against Oxoid
standard disks and the agar dilution (mg/l) for gentamicin (4 and 8),
kanamycin (6 and 25), amikacin (16 and 32), netilmicin (12 and 32).
ciprofloxacin (1 and 4), clarithromycin (2 and 8). lincomycin (1 and 8) and
erythromycin (15 /Lg disk).
Results: From 25/60 SA and 31150 CNS Oxa 4 mg/l resistant isolates there
was as resistant strains: 22/25 SA and 27/31 CNS to aminoglycosides (almost
all with Gen Kan Amk phenotype). 20/25 SA and 15/31 CNS to cipro-
floxacin and 19125 SA (14 inducible) and 23132 CNS (7 inducible) to MLSB.
For oxacillin susceptible strains the figures was respectively for aminoglyco-
sides 11/35 SA (phenotype Kan) and 7/19 CNS, for quinolones 4/35 SA and
2/19 CNS and for MlSB group 7135 SA and 11/19 CNS.
Conclusion: With a good agreement between techniques for aminogIyco-
sides and quiolones it is needed to test reducibility for MLSB.
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IWeP39IConjugative resistance to tazobaetam plus
piperacillin among extended-spectrum beta-Iaetamase
produdng nosocomial Klebsiella pneumoniae
Sella <;:etinAkhan. Fig"n Co~kunkan, OzlemTansei. Haluk Vahaboglu
Klinik Bakteriyoloji ve Infeksiyon Hasta"klam AD, Kocaeli Universitesi,
Istanbul, Tllrkey
Objective: To demonstrate the genetic location and enzymatic character-
istics of piperacillin-tazobactam resistance in extended-spectrum beta-Iacta-
mase (ESBL) producing nosocomial Klebsiella isolates.
Methods: Transconjugation experiments were studied on agar media and
the recipients were selected on Mueller-Hinton agars supplemented by
rifampicin plus either ceftazidime or piperacillin. Isoelectric-focusing were
achieved on acrylamide/bis-acrylamide gels having ampholytes with pi
range of 3 to 10. Minimal inhibitor concentrations of antibiotics were
determined by agar dilution method. TEM genes from the isolates were
amplified by polymerase chain reaction.
Results: A total of3O ESBl producing Klebsiella pneumoniae from different
hospitals were studied. From these. we obtained 7 transconjugates resistant
to piperacillin-tazobactam, 23 to ceftazidime plus tazobactam (also to
piperacillin-tazobactam) and 10 to only ceftazidime. Piperacillin-tazobac-
tam resistant isolates were producing a single enzyme with pi point of 5.4.
All of these were blaTEM positive and the sequence ofa single amplification
product was identical to TEM-l.
Conclusion: The ubiquitous classical beta-Iactamase TEM-I is responsible
from the conjugative resistance of ESBL producing Klebsiel'" pneumonia. to
tazobactam in Turkish hospitals.
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IWeP40 I Meropenem-induced morphological changes in
E. coli
J. BU~SI, A. S. M. Dofferho~, A. M. Horrevorts1,J. W. M. van der
Meer
'Canisius-Wilhelmina Hospital; 2University Medical Center, NijmeJlell,
Netherlands
Objectives: Meropenem is a carbapenem that binds to Penicillin-binding-
proteins (PBP)-2 and -3 of Gram-negative bacteria. According to that
binding pattern, meropenem may induce spheroplast- and filament-forma-
tion, respectively. Alteration of morphology may influence pathogenicity
by change of endotoxin-liberating capacity and growth-patterns.
Methods: In three in-vitro experiments, we exposed cultures of E. coli
ATCC 25922. containing 5 x 106 CFU/ml, to meropenem at dose-levels:
14x. 7x. 4x, 2x, 1x. 0.5x, 0.25x, 0.125x and 0.0625 x MIC. After 2. 4, 8
and 24 hours of incubation, specimen were taken for Gram-stains and
measurements of bacterial outgrowth. In a control-experiment bacteria
were exposed to O.sx MIC ceftazidime to verify antibiotic-induced fila-
ment-formation.
Results: Cultures were sterile after 4 hours of incubation using 7x MIC or
more. After 4 hours bacterial debris was seen at 7x and 14x MIC.
Morphology of the bacteria changed to spherical cells (spheroplasts) at all
other dosage-levels. while in the control-experiment large filaments were
seen. Morphology after 24 hours did not differ from the first four hours.
Conclusions: Although meropenem is both a PBP-2- and PBP-3-binder,
we did not demonstrate ftlament-formation. The affinity to PBP-2 must be
higher than to PBP-3 in E. coli. This might be advantageous compared to
filament-inducing ,B-lactams. because spheroplasts liberate less endotoxin
from their cell-wall and are thus expected to be less pathogenic. Although
the bacteria are morphologically altered. they do not loose their growth
capacity.
IWeP41 IMeropenem susceptibility is retained after 3 years of
use: Current European results from the MYSnC (Meropenem
Yearly Susceptibility Test Information Collection) study
P.J. Turner,J. M. Greenhalgh. G. D. Hughes
AstraZeneca, Mace/effield, United Kingdom
MYSTIC is a worldwide surveillance programme which examines the
activity of meropenem and comparators against bacterial isolates from
various hospital units where meropenem is prescribed. These centres include
intensive care units (ICUs), neutropenia centres, cystic fibrosis units and
general wards. Centres test up to 100 Gram-positive aerobes and 100 Gram-
negative aerobes against a set of antibiotics at the same time each year. In
Europe, 9, 11 and 9 centres have reported results for 3, 2 and 1 year.
respeetively. Comparison of combined results for Years I, 2 and 3 of
MYSTIC show that, whether using median MIC value (MMIC) or
MIC90 (mg/L). meropenem retains its activity against the majority of the
organisms isolated (Table1). Conversely, but consistent with much of the
published data, evidence of resistance to cephalosporins, ,B-lactam/,B-laeta-
mase inhibitor combinations, aminoglycosides and fluoroquinolones is
observed in all years and in all centres.
Table 1
First Year Second Year Third Year
MMl- MI- MMI- MI- MMI- MI-
Organism n C C90 n C C90 n C C90
S. aurfUS 630 0.13 0.25 387 0.13 0.25 253 0.13 0.25
S. (coag-neg) 228 0.13 8 156 0.06 16 73 I 4
E·faecalis 262 8 32 215 8 16 127 4 16
E. coli 443 0.016 0.13 341 0.06 0.13 63 0.03 0.03
K. pneumoniae 172 0.03 0.13 145 0.03 0.13 87 0.03 1
E. cloacae 156 0.06 0.25 141 0.06 0.13 67 0.03 0.25
S. marcesltns 101 0.06 0.5 62 0.13 0.13 51 0.06 0.13
P. mirabilis 93 0.06 1 66 0.13 0.13 67 0.06 0.25
P. aeruginosa 782 0.5 16 740 2 16 282 1 8
The results indicate that meropenem is retaining its broad spectrum and
potency in centres that are active prescribers, unlike many of the compara-
tors.
[WeP42IDetection of extended-spectrum p-Iactamase (ESBL)
by cefepime and amoxidllin-clavulanate
M. Dizbay. R. Karakus, D. Arman
Department ofClinical MicrobioloJlY and Infectious Diseases, Gazi University
Faculty ofMedecine, A"kara, Turkey
Objective: To demonstrate the in vitro iJ-Lactamase stability of cefepime.
Methods: Klebsiella species, Escherichia coli and Pseudomonas aeruginosa
strains isolated in 1999 as etiologic agents of nosocomial infections were
enrolled in the study. Antimicrobial susceptibility was investigated by disk
diffusion technique and ESBL activity was investigated by double disk
synergy method using amoxicillin-c1avulanat (AMC), ceftazidimc (CAZ),
cefotaxime (CTX), cefepime (FEP) and aztrconam (ATM) disks.
Results: ESBL production was observed in 8/47 P. aeruginosa, 11/33
Klebsiella spp. and 9/74 E. coli isolates. Number ofESBL producing strains
for each of the antibiotic tested are represented on the table.
No ofESBL producing strains
n ESBL
(+)fTotal FEP CTX ATM CAZ
E. coli 9/74 8 8 7 7
Klebsiella spp. 11/33 11 8 8 3
P. aeruginosa 8/47 8 2 2 2
Total 28/154 27 18 17 12
According to the criteria ofNCCLS; 1/8 P. aeruginosa, 7/1 1 Klebsiella spp
and all of (9/9) E. coli strains were interpreted as susceptible to cefepime
despite ESBL activity.
Conclusions: ESBL which can hydrolyze cefepime is prevalant in our
hospital. ESBL frequency in P. aeruginosa that can hydrolyze only FEP is
an unusual finding. Relatively low frequency ofESBL among P. aeruginosa
strains in previous trials may be due to not testing cefepime as a substrate. In
the treatment of infections caused by potentially resistant microorganisms
due to ESBL production. cefepime must be used with caution, even with
susceptible in vitro results.
IWeP43 I Susceptibility of E. coli isolated from uncomplicated
urinary tract Infections (un) to meclilinam and seven other
antibiotics
R. Skov l , L. Bjeragerl , F. Espersen l • N. Frimodt-M0lle,z
I Development ofResearch and Developmrnt; 2Clinical Microbiology, Statens
Serum Insli'u" CopO/hagen, Denmark
There is considerable concern about the increasing levels of antimicrobial
resistance, especially against the fluoroquinoloncs. As part of two studies of
treatment of uncomplicated UTI we assessed the susceptibility of E. coli to
eight antibiotics commonly used for treating uncomplicated UTI.
Material and methods: A total of574 isolates ofE. coli from uncomplicated
UTI from 6 centres in five countries (UK (2), Sweden, France, Portugal and
Greece) were tested against the following antibiotics: ampicillin, amoxy-
cillin-/c1avulanic acid, mecillinam, sulfonamide. trimethoprim, sulfa-
methoxazole-/trimethoprim, nirrofUrantion and ciprofloxacin by agar
diffusion using Rosco Neosensitabs on Danish Blood Agar. For mecillinam
this medium tends to give false resistant results, and such strains were retested
on Isosensitest agar using 25 Jlg disks and/or E-test. The susceptibility was
determined using the guidelines from Rosco and the guidelines issued by the
Swedish Reference Group for Antibiotics (SRGA).
Results: The frequency of resistance was: ampicillin 38%, amoxycillin-/
c1avulanic acid 2%, mccillinam 2%, sulfonamide 44%, trimethoprim 21 %,
sulfamethoxazole/trirnethoprim 18%, nitrofurantoin 15% and ciprofloxa-
cin 2%.
Conclusion: Resistance to mecillinam for E. coli continues to be low, and has
the same level as for quinolones making mecillinam a suitable first choice
alternative for uncomplicated UTI, thereby reserving the usc offlouroqui-
nolones for severe systemic infections.
IWeP44!/n vitro susceptibility testing of mecillinam using
Neosensitabs® on Mueller Hinton agar
R. Skovl , F. Espersenl , N. Frimodt-Maller2
'Department.< ofResearch and Development; 2Clini!al Microbiology, Statens
Serum Inslilul, Copenhagen, Denmark
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MEM and IMI showed the lowest MIC90 for the strains tested and were
the most active antibiotics showing no observed reduction in susceptibilities
over 3 years. The high rates ofresistance demonstrated with other antibiotics
indicate that the earbapenems are appropriate as first choice in the manage-
ment of serious infection in UK ICUs.
meropenem (MEM) against six other antibiotics. A total of 205 Gram
positive (GP) isolates consisting of 20 species and 301 Gram negative (GN)
strains covering 34 species have been studied. Amongst the GN species, P.
aeruginosa (n = 50), E. coli (n = 48), E. cloacae (n = 34) and A. baumanii (n =
31) were the most prevalent whereas S. aureus (n = 73) and coagulase
negative staphylococci (n = 64) were the most common GP i;olates.
Overall, the isolates showed the following percentage susceptibilities to
the antibiotics tested:
MEM IMI CTX TAZ CIP GEN
70.2
75.4
73.6
69.6
82.4
77.9
77.6
58.1
64.9
73.9
49.8
58.2
CEF
35.4
62.1
52.8
86.9
99.0
94.11
83.9
95.7
94.6
GP .train.*
GN strains**
Total
Mecillinam is an alternative first choice antibiotic for the treatment of
urinary tract infections. In this study we validated the zone diameter
breakpoints proposed by Rasco for Neosensitabs, for confluent inoculum
on Mueller Hinton agar.
Material and Methods: A total of 495 EnrerobacteriaceaL (149 E. coli, 46
Citrobactrr spp., 86 Klebsiella spp., 82 EntrrobaClrr spp., 18 M. morganii. 49 P.
mirabi/is, 24 P. vulgaris, 19 Providencia spp., and 22 Serratia spp.) were tested.
Agar dilution and tablet diffusion with mecillinam Neosensitabs<l!l, were
performed on Mueller Hinton BBL II agar, using the methodology outlined
by Rosco i.e. confluent inoculum, and ambient overnight incubation.
Results: Using the breakpoints recommended by Rosco i.e. Resistant> 16
Jlg/ml corresponding to < 16 mm and Susceptible < 4 Jlg/ml correspond-
ing to > 20 mm a total of29 (6%) very major errors (VME) and 2 major
errors (ME) were found. However, 22 (76%) of the VME were found in
only two species. For Klebsiella spp. 15 out of86 strains gave VME and for M.
morganii 7 out of 18 gave VME. However, for E. coli the predominant
uropathogen, a high correlation between the zone size and the MIC was
found as well as only one VME.
Conduslon: This study indicates that susceptibility testing of mecillinam
using Neosensitabs® on MH performs well for EnterobaClfriaCfa, but gives
significant errors for Klebsiella spp. and M. morganii.
Conclusions: Results indicate the sustained potency and spectrum of activ-
ity of MEM over a broad geographic range despite its use in treating
seriously ill patients. Carbapenems appear to be a reliable option for the
initial empirical treatment of serious infection.
IWeP4S1 Global trends in an antimicrobial resistance
surveillance system: Results from the MYSTIC programme
M. A. Pfaller, R. N.Jones
University of Iowa College ofMedicine and CAST Laboratories, Iowa City,
Iowa, United States
Objectives: To provide a summary of in vitro activity of meropenem
(MEM) and eight comparative antimicrobial agents against over 9,000
clinical isolates obtained in 1999 from 47 study centres in Europe, Brazil,
Mexico, the USA, Israel, Hong Kong and Thailand. Centres included
intensive care units, cystic fibrosis units, neutropenia centres and general
wards, and were all active users of MEM.
Methods: MICs for MEM and eight other antibiotics were determined for
up to 100 aerobic Gram-negative isolates and 100 Gram-positive isolates at
each centre using NCCLS recommended broth or agar dilution methods.
Results: MEM and IMI retained their broad spectrum and potency, inhibit-
ing ~84% of all isolates irrespective of the geographic region. Compared
with in vitro data obtained prior to the introduction of MEM in Europe and
USA. there was no diminution in the spectrum or potency ofMEM whereas
the cephalosporins and ~Iactamase inhibitor combinations lost activity in
many countries. Percentage susceptibilities for the nine agenn [e.[cd again..
all pathogens arc shown below.
MEM IMI CTX CAZ CPE TAZ CIP GEN TM
Americas
Europe
Others
96
89
93
95
88
84
84
61
64
86
71
61
92
76
75
88
74
75
83
71
66
89
69
54
86
69
51
IWeP47I German results (1997-99) from the MYSTIC
(Meropenem Yearly Susceptibility Test Information Collection)
study
B. Grabein
Max von Pettenkofer-Institutfiir Hygiene und Medizinische Mikrobiologie der
Ludwig-Maximilians-Universitiit, Miinchen, Germany
Objective: Multicenter, longitudinal surveillance of the activity of mero-
penem compared to nine other antimicrobial agents against Gram-positive
and Gram-negative clinical isolates from intensive care or haematology/
oncology patients.
Methods: The MICs of 10 antibiotics for 200 clinically significant, con-
secutive, no-copy isolates per year (1997-1999) from seven, meropenem-
prescribing hospitals in Germany, were determined by broth microdilution
following NCCLS guidelines.
Results: A total of 1084 Gram-positive strains (including 490 S. aureus and
336 enterococci) and 1525 Gram-negative strains (837 Enterobacteriaceae,
614 P. aeruginosa, 74 other) were analysed over 3 years. Meropenem was
active at concentrations between 0.125 mg/L and 0.5 mg/L against methi-
cillin-susceptible S. aureus (MSSA) and all Enterobacteriaceae (including~
lacraolasc-produdng :strains), while non-carbapenem ~ts showed vary-
ing levels of resistance to the Enterobacteriaceae. For S. aureus only
imipenem was comparably active. For ~Iactamase-producingEnterobacter
cloacae, only cefepime (MIC90 4 mgfL) and ciprofloxacin (MIC90 0.25 mg/
L) had comparable MIC distributions. The majority ofE. faecalis strains had
MICs for meropenem between 1 mg/L and 16 mg/L (range 0.032 to > 128
mg/L) with piperacillin/tazobactam being the most active agent tested
(range 0.25 to > 128 mg/L, commonest values 0.5 to 8 mg/L). Most P.
aerugillosa strains had MICs for meropenem between 0.064 mg/L and 16 mg/
L (range 0.032-64 mg/L), ciprofloxacin being slightly more active.
COnclusions: Meropenem remained highly active in vitro against MSSA, all
Enterobacteriaceae and P. aeruginosa. Activity was not influenced by ~
lactamase production. There was no observed reduction in meropenem
activity over a 3-year observation period.
IWeP46IMeropenem susceptibility of bacterial isolates from
the UK part of the MYSTIC antimicrobial surveillance
programme 1997-1999
R. G. Masterton
UK MYSTIC Study Group; Western General Hospital. Edinburgh, United
Kingdom
The MYSTIC (Meropenem Yearly Susceptibility Test Information Collec-
tion) study is a longitudinal project that gathers antibiotic susceptibility data
from specific types of clinical units that are all users of meropenem. Data
monitoring bacterial antimicrobial resisrance patterns in intensive care units
(ICUs) is essential as ICUs experience significant and increasing problems
due to their high incidence of infection, compromised patients and heavy.
broad-spectrum antibiotic usage. Over 3 years, 506 aerobic, distinct,
bacterial clinical isolates from UK ICUs have been investigated. Using
NCCLS methodology. the MICs of these strains were determined for
IWeP48I Determining beta lactam resistance among gram
negative isolates in the PhoenixTM 100 System
T. Wiles,]. Hejna, M. Gosnell. C. Yu, V. Kennedy
BD Bioscietlus, Sparks, MD, United States
Objectives: To determine beta lactam resistance among gram negative
isolates using the PhoenixTM 100 Automated Microbiology System that
is currently under development.
Methods: Phoenix Susceptibility test results of 210 gram-negative strains
that included a challenge set of 110 isolates with known resistance mechan-
isms and 100 recently acquired clinical isolates were compared to results
obtained with a NCCLS recommended Standard Broth Microdilution
(SSM) method. Doubling concentrations of Ampicillin, Amoxicillin.
Ticarcillin, Piperacillin, lmipcnem and Meropenem were tested in both
Phoenix and SBM,
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[WeP521 Comparative in vitro activity of cefepime, with other
antimicrobials against nosocomial isolates of Enterobac:tedacNe
Po aeruginosa, and Adnetobacter
M. Gelfand!, K. E. Aldridge2, S. Davis!, D. Ashcraft2
IMethodist Hosp., Memphis, TN; 2LSU Med. Ctr., New Orleans, LA,
United States
The superior in vitro activity ofPip/Tazo in comparison to the combina-
tion Cef/Metro was due to a much better activity against Pseudomonas
aeruginosa and Enterococcus spp. For all other pathogens Pip/Tazo and Cef/
Metro showed equivalent in vitro activity.
Conclusion: The study provides evidence that Pip/Tazo has excellent in vitro
activity against pathogens commonly isolated from pediatric intra-abdom-
inal infections in Europe and South Africa. Pip/Tazo was found to be
superior to Pip alone. The superior activity to a commonly used antibiotic
regimen (Cef/Met) was due to its enhanced activity against Pseudomonas
aeruginosa and Enterococcus spp. The study also provides current epide-
miologic data on the resistance of pathogens in Europe and South Africa
against the four antibiotics tested
IWeP511tn vitro activity of plperadllinltazobactam in
comparison to cefotaxime plus metronidazole against dinical
isolates of pediatric intra-abdomInal Infections In Europe and
South Africa
G. Dobler l , T. Linglof
t Tazosin Pediatric Intra-abdominal Infection Study Group Genetics Institute
Martinsried, Germany; 2University Hospital Uppsala, Sweden
Objective: As part ofa clinical study in 13 European countries and in South
Africa ill vitro data were obtained on antibacterial activity of Piperacillin
(Pip). PiperaciIlin/Tazobactam (Pip/Tazo) and Cefotaxime plus Metroni-
dazole (Cef/Metro) in pathogens isolated from pediatric intra-abdominal
infections.
Methods; E test was used according to the standards of NCCLS.
Results: 864, 881, and 908 pathogens (92 species, 32 genera) were tested
against Cef/Metro, Pip and Pip/Tazo, respectively. The overall rates of
sensitivity, intermediate sensitivity, and resistance are given below:
objectives: This study was performed to compare the activity ofcefepime,
the only marketed 4th generation cephalosporin, with that of other
antimicrobials used in nosocomial infections.
Methods; MIC values were determined using a broth microdilution
method and interpreted by NCCLS recommendations. Antimicrobials
tested were cefepime (CEF), ceftazidime (TAZ), ceftriaxone (TRI), cefti-
zoxime (ZOX), ampicillin/sulbactam (A/S), ciprofloxacin (CIP), gentami-
cin (GE), ofloxacin (OF), and trimethoprim/sulfamethoxazole (TMP/
SMZ). Over 500 nosocomial isolates were tested comprising enterics - 279
isolates; P. aeruginosa -130 isolates; and A. baumanii - 127 isolates.
Results: CEF showed excellent activity against enterics with MIC90's ~
0.06-2 Jlg/ml among the various species and no resistant isolates were
detected. By comparison (MIC90's), against enterics CEF was from 4-128-
fold, 0-64-fold, 0-256-fold, and 4-512-fold more active than TAZ, TRI,
ZOX, and A/S, respectively. Resistance rates (%R) ranged from 0-37% 0-
22%,0-39%, and 0-75% for TAZ, TRI, ZOX, and A/S. CEF was more
active than CIP, OF, GE, and TMP/SMZ with the latter agents having %R
up to 19%, 19%, 10%, and 22% respectively. Against P. aeruginosa CEF
(6%R) was 4-to 8-fold more active than TAZ (22%R), TRI (18%R), ZOX
(83%R), and A/S (97%R). For Acinelobacter %R was as follows: CEF-28%;
TAZ-87%; TRI-79%; ZOX-77%; CIP-82%; OF-82%; GE-78%; and
TMP/SMZ-84%.
Condusions; CEF, a new cephalosporin resistant to many /3-lactamases
active against 3rd generation cephalosporins, was active against all enteric
isolates as well as most P. aeruginosa. CEF had equal or superior activity to
comparator antimicrobials.
17.1%
1.9%
6.9%
7.5%
0.3%
3.5%
75.4%
97.8%
89.6%
Percentage ofstrains
Sensitive Int. sensitive Resistant
Piperacillin
Pip{fazobac
Cef+ Metro
E. Giacobonel , E. Romerol , 1. Franchin02
IMYSTIC (Meropenem Yearly Susceptibility Test Information Colledion
project study); ICRSS Policlinico S. Malteo Pavia; 2AstraZeneca Milano, Italy
Objectives: In order to evaluate the type ofpathogens causing infections and
the profile and trend ofantimicrobial susceptibility ofbacteria isolated from
neutropenic patients in haematology wards, during 1997 and 1998, an
accurate study was performed.
Methods: Only microrganisms isolated from neutropenic patients in hae-
matology wards was inserted in this study. Bacterial identification and
antibiotic susceptibility assays were performed by standard laboratory
techniques. Antibiotic breakpoints were utilised according to NCCLS
guidelines.
Results: During the first year of study 172 microrganisms (40 Gram-
positive and 132 Gram-negative) and in the second year 192 microrganisms
(26 Grampositive and 166 Gram-negative) were isolated from neutropenic
patients. In both years of study, Pseudomonas aeruginosa Escherichia coli and
Staphylococcus aureus were the most isolated microrganisms representing
more than 50% ofall the isolates. Meropenem showed an excellent activity
against Gram-negative isolates with more than 92% susceptibility. lmipe-
nem and pip/tazobactam showed better activity against Gram-positive
followed by meropenem.
Condusions; Our findings indicate that meropenem which has been avail-
able in Italy since the end 1994 still retains a high level of activity against
many Gram-positive and Gram-negative bacteria isolated from neutropenic
patients. Therefore, meropenem can be used in the empiric treatment of
severe infections in haematology wards, where the diffusion ofmultiresistant
pathogens needs the use of an efficient, no-toxic and potent antibiotic.
D. Turner, T. Wiles, M. Votta,]. Reuben
BD Biosciences, Sparks, MD, United States
Objective; To evaluate the ability of the Phoenix8 Automated Microbiol-
ogy System (currently under development) to detect the presence of
extended-spectrum beta-laetamases (ESBLs) in E. coli, K. pneumoniae and
K.oxytoca.
Methods: Eighty-eight isolates, including 58 E. coli, 24 K. pneumoniae and
6 K. oxytoca were tested for the presence of Extended Spectrum Beta
Lactamase (ESBL). This set included twenty-two different ESBL strains. The
reference was performed in accordance with NCCLS guidelines for the
detection of ESBL producing isolates. Phoenix panels were tested with
approximately 5 x 105 cfu/ml of inoculum. Reference panels were read
after 16 to 20 hours of incubation at 35 degrees centigrade. Phoenix panels
were interpreted by the Phoenix instrument.
Results; Phoenix correctly determined the ESBL outcome for 11 out of 12
(92%) ESBL positive and 39 out of42 (93%) ESBL negative E. coli. Ofthe 6
K. oxytoca tested 3 were indicated as ESBL positive by the reference
method. Phoenix correctly determined the outcome for aU six K. oxytoca
tested (100%). Of the 24 K. pneumoniae tested 16 were indicated as ESBL
positive by the reference method. Phoenix correctly determined the ESBL
outcome for all 24 K. pneumoniae tested (100%). When compared to the
reference method Phoenix achieved a sensitivity of97% and specificity of
95%. Phoenix results were determined in 4 to 8 hours.
Conclusion: The Phoenix system is capable of accurately and rapidly
detecting ESBL producing isolates of E. coli, K. pneumoniae and K.
oxytoca.
Results: The overall essential agreement ranged from 91 to 97%. Catego-
rical agreement was from 95 to 100%. One very major error was observed
with Ticarcillin (1 %) and one with Piperacillin (1.3%). No other very major
errors were observed. The major error rates were as follows: Ampicillin
(2.1 %), Amoxicillin (2.5%), Ticarcillin (4.0%), Piperacillin (3.1 "!o), Irnipe-
nem (0.6%) and Meropenem (0%).
Conclusions: The observations in this study indicate an acceptable level of
performance in the detection ofgram negative resistance to the beta-lactam
antibiotics.
IWeP50 lin vitro activity of meropenem against bacteria
isolated from neutropenic patients
IWeP49I Detection of ESBL produdng E. coli and Klebsiella in
the Phoenix8 100 Automated Microbiology System
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lWepsJJ Comparison of in vitro activity of piperacillinl
tazobactam (pm, ticarcillinldavulanate mo, ampicillinl
sulbactam (AlS), ceftrlaxone (CTR), ofloxacin (OFL), and
imipanem (IMP) against nosocomial isolates
K. E. Aldridge', M. Gelfand2, S. Davis2, D. Ashcraft'
'LSU Med Ct,. New Orleans, LA; 2Methodist Hospital, Memphis, TN,
United Stares
Objectives: To establish the degree of antimicrobial resistance (%R) to
various broad-spectrum agents used to treat nosocomial infections.
Methods: Test isolates were comprised of Enterobaaeriauae (enterics)-279
isolates; P. ae,uginosa (PA)-I30 isolates; A. baumanii (AB)-127 isolates; and S.
maltophilia (SM)-35 isolates. MIC values were determined by a broth
microdilution method and interpreted by NCCLS recommendations.
Results: Against enterics PIT (R = 0-19%) was more active than T/C (R
= 0-44%) and A/S (R = 0-76%) particularly isolates of Enrerobacter, E.
coli, and Serraria. A/S was less active than PIT against Citrobacter (%R =
37v19) and K. pneumoniae (%R = 12v5). CTR and OFL had similar activity
to PIT with the exception of E. cloacae (CTR-%R-22%) (OFL-%R-19%).
K. pneumoniae and S. marcescens were more resistant to OFL than PIT. CTR
and PIT had similar activity to IMP except for some Cit,obacte, and
Enre,obacle, isolates. Against PA isolates PIT (%R = 4%) was the most
active agent compared to %R = IS to 97% for the other agents. Against SM
and AB a wide range of%R was noted with IMP, T/C, and PIT being the
most active.
Condusions: These data confum the high level of %R exhibited among
nosocomial isolates and that ongoing susceptibility studies are needed
confirm the most active antimicrobials.
lWePs4] Comparative in vitro activity of MK-G826 (L-749,345),
a new carbapenem, against nosocomial isolates of
Enterobacteriaceae
K. E. Aldridge', D. Ashcraft', S. Davis2, M. Gelfand2
ILSU Med. Ct,., New O,leans, LA; 2Me1hodisr Hosp., Memphis, TN,
Unired Srares
Objectives: MK-0826 is a new carbapenem antimicrobial which is resistant
to hydrolysis by many broad-, and extended-spectrum beta-Iactamases. This
study was designed to compare the in vitro activity of MK-0826 to other
commonly used antimicrobials for therapy of nosocomial infections.
Methods: A tota] of 138 nonduplicate isol:lt~W'e're collected from patients
only after the patient had been hospitalized 72 hrs or greater. Isolates were
cultured from blood, other body fluids, wounds, sputum, and tissues. All
is~lates .we~e tested for t~eir susceptibility to antimicrobials using a broth
mICrod,lutlon method WIth a inoculum size of 5 x 104 CFU/well. MIC
values were interpreted based on NCCLS recommendations.
Results: MK-0826 was active against all the test groups of isolates with
MIC90 values ranging from ~O.25-0.5 Ilg/ml: E. coli (0.25); E. ae,ogenes
(0.5); E. cloacae (0.5); K. pneumon;ae (0.25); P. mi,abilis (~0.25); S. marcescens
(~0.25). By comparison (MIC9O's) MK-0826 was more active than imipe-
nem (2-tol6-fold), gentamicin (2-to 32-fold), ticarcillin/cIavulanate (2-to
1024-fold) a~ainst each test group and overall more active than ciproflox-
aCID, ofloxacm, and trimethoprim/sulfamethoxazole.
Condusions: MK-0826 was highly active against enteric isolates from
nosocomial infections which often produce extended-spectrum beta-lacta-
mases. M~-0826 had equal activity to meropenem while being more active
than a vanety of other commonly used antimicrobials.
IWepssl Dissemination and evolution of new, plasmid-
mediated extended-spectrum ,8-lactamases among
Enterobacteriaceae isolates from the People's Republic of China
A. Chanaw~ngl, F. H. M'Zali',]. Heritage·,]. H. Xiong2, M. Allen3, P.
M. Hawkey
IDi,,~s~on ojMicr~biolog~.Unive,siry ojLeeds, Leeds, United Kingdom; 2Pi,sr
Mutll"pal People s Hosp.ral oJGuangzhou, China; JWyerh Labo,aro,ies,
Maidmhead, United Kingdom
Objectives: To char~creriseextended-spectrum p-Iactamases (ESBLs) pro-
duced by Enterobacteriaceae isolates from the People's Republic of China
(China).
Methods: Fifteen clinical isolates were collected from the First Municipal
People's Hospital of Guangzhou, China. All isolates were positive for the
augmentation test. They were further investigated for phenotypic and
genotypic characteristics.
Results: Six isolates (40%) produced SHV-12 and nine isolates (60%)
produced non-TEM and non-SHY ESBLs. These nine isolates included
five Eschuichia coli, three Klebsiella pneumoniae and one Emerobaeter ae,ogenes.
All isolates showed MICs ofcefotaxime higher than those ofceftazidime. In
an isogenic E. coli background expressing the ESBLs from these clinical
isolates, the geometric mean MIC for cefotaxime was 16 mgL-I compared
with a geometric mean MIC of I mgL-, for ceftazidime. All nine non-
TEM, non-SHV isolates carried a blaCTX-M gene as shown by PCR
amplification. Of the six isolates producing SHV-12, three were found to
produce CTX-M p-Iactamase also. Nucleotide sequence analysis of repre-
sentative isolates revealed that they produced different, novel CTX-M-Iike
enzymes, which have close homology to TOHO-2 and CTX-M-7. The
CTX-M-producing isolates were characterised by a PCR-RFLP technique.
There were three novel CTX-M p-lactamases found in this study, as
confirmed by sequencing.
Conclusions: This is the first report ofCTX-M ESBL. in China. These Far
East strains show widespread dissemination of the blaCTX-M gene amongst
at least 3 species ofEnterobacteriaceae and also demonstr~te the evolution of
these genes in a relatively restricted geographical location.
IWePS61 Low anity of PBP3 is responsible for the expression
of borderline methidllin resistance in a Staphylococcus
epidermidis dinical strain
E. Petinaki, G. 0]. Dimitracopoulos, I. Spiliopoulou
Depa,tment ojMicrobiology, School ojMedicine, University ojPatras, G,w:e
Objectives: The purpose of this study was the anaIysis ofbinding-affinity to
beta-Iactams of penicillin binding proteins (PBPs) in two borderline methi-
cillin resistant S. epide,midis clinical strains.
Materials-Methods: Two S. epidermidis clinical strains expressing border-
line methicillin resistance (MIC: 4llg/ml) and a sensitive one as control, were
isolated from clinical specimens in the Microbiology Laboratory at the
University Hospital ofPatras. The isolates were examined for the presence of
mecA gene by pCR. Analysis of the binding affinity of their PBPs was
performed by f1uorography in a competition assay, using ["H]penicillin in
the presence ofvarious concentrations ofmethicillin, ranged from 0.5 to 800
Ilg/ml. The density of radiolabeled PBPs at each concentration was mea-
sured by scanning densitometry.
Results: The prcx.ncc of mccA gene was detected only in one horderline
strain. The f1uorographic analysis of PBPs of this strain showed five bands
(pBPI, PBP2, PBPZa, PBP3, PBP4). The protein having the lower affinity
among PBPs was PBP2a (IC50: 200 Ilg/ml). Four bands (pBPt, PBP2,
PBp3, PBP4) were detected in the mecA-negative strain as in the sensitive
one. The protein having the lower affinity in the mecA-negative borderline
strain was pBP3 (IC50: 40 Ilg/ml). The remaining pBPs of this strain had
similar affinity compared with those of the sensitive isolate.
Conduslon: The lower affinity of PBP3 is another mechanism involved in
borderline methicillin resistance among S. epidermidis strains. This mechan-
ism is less aggressive than the presence of mecA gene, for the spread of
methicillin resistance.
IWePS7! Betalactam resistant Haemophilus influenzae in
Sweden
B. Olsson-Liljequist, L. Gezelius, A. Syk
Smillskyddsinsrirutet, Solna, Sweden
Obj~~es: To investigate betalactam resistant but betalactamase negative
climcallsol~tes of Haemophilus influenzae (HI) in Sweden for phenotypic
and epidemiolOgIcal characteristics.
Methods: 200 isolates, with penicillin V (PV) zones < to mm and/or
loracarbef (LO) zones < 20 mm, were collected from 27 Swedish micro-
biology laboratories in 1997. Agar dilution MICs were determined for
ampicillin (AM), PV, LO, cefuroxime (XM) ~nd cefouxime (CT). Biotyp-
":Ig (mdole, urease, 00), pCR for capsular typing, and long PCR-
nbotypmg were used for strain characterization for epidemiological pur-
poses.
Results: The strains, all from respiratory tract, were isolated from children
« 10 y) 53% and from adults (25-80 y) 45%. More than 90% ofthe strains
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were inhibited by PV 16-64 mgfL, AM 1-4 mg/L, La 16-64 mg/L, XM 2-
8 mg/L, CT 0.016-0.12 mg/L. Except for CT, the median values differed 3-
5 dilution steps from corresponding values for susceptible HI. Nine of the
strains had both betalactamase- and nonbetalactamase-mediated resistance,
as verified by using clavulanic acid. Biotype 2 and 3 dominated (29 and
60%), and only 3 strains were encapsulated (type f). Four resistance (R)
phenotypes based on inhibition zones ofPV and La were distinguished, the
cephalosporin-R phenotype being most common. More than 10 band
patterns were identified using long-PCR-ribotyping on 110 strains from
11 laboratories. Correlation was seen between cerrain R-phenotypes and
ribotyping patterns.
Conclusion: Disk diffusion with PV and La was able to identify non-
betalactamase mediated resistance in HI, even in the presence of betalacta-
mase. The R-phenotyping in combination with a molecular typing method
should be useful tools for identifying resistant organisms.
IWeP5S! Bacterial activity of cefepime plus amikadn against
extended spectrum beta-lactamase produdng Klebsiella
pneumoniae (ESBL-Kp)
L. Martinez-Martinez\ A. I. Suarez!, J. Benedi2, A. Pascual l
tDpt of Microbiology, School ofMedicine University Hospital ofSeville;
2University of l/les Balears, Spain
Objectives: The activities of cefepime (FEP), ceftazidime (CAZ), cefotax-
ime (CTX), amikacin (AK) and of the combination of the three cephalos-
porins plus AK against 30 clinical isolates of ESBl-Kp (15 porin expressing
[P + 1and 15 porin defficient strains [P-J) were determined.
Methods: Kp isolates were considered to produce ESBL when the MIC of
either CAZ and/or CTX decreased $8 times in the presence of c1avulanic
acid (4 mg/I). Porin expression was determined by SDS-PAGE of outer
membrane proteins. Susceptibility assays were performed by microdilution
using lOS and 107 cfu/ml as inocula. MICs and MBCs were determined
according to NCCLS guidelines. Synergy studies were performed by a
checkerboard assay. For two isogenic strains (P + and P-) a killing curve
assay was also performed.
Results: The activities ofcephalosporins, but not ofAK, was affected by the
inoculum size. The combination ofFEP, CAZ or CTX with AK showed a
synergistic effet against 40%,53% and 40% ofP+ strains respectively. An
additive effect was obtained for 60%, 47% and 60% ofP + strains. For P-
strains an additive effect was observed agaist 100%, 87% and 100% of the
strains. No antagonism was observed for any combination. All three
combinations showed an additive effect against the two isogenic Kp strains
(P + and P-) strains. This additive effect was confIrmed by the killing curve
assay.
Conclusions: The combination of FEP, CAZ and CTX with AK showed
either synergistic or additive effect against P + Kp strains and additive effect
against P- KP strains.
IWeP59IExtended-spectrum beta-Iactamases (ESBLs) in
clinical isolates of E. coli and K. pneumoniae
E. Chinou, M. Georgouli, N. Trobouki, E. Tsiganou, H. Skouteli, P.
Golemati
Department of Microbiology, "Saint Savvas" Hospital, Athens, Greece
Objectives: To evaluate the emergence of E. coli and K. pneumoniae isolates
which produce ESBls in an anticancer hospital and their in vitro suscept-
ibility to antimicrobials over a 2-years period.
Methods: Five hundred and two E. coli and 93 K. pneumoniae strains were
isolated from 552 patients in our hospital. The strains were identified using
Api 20E and were tested by the disk diffusion method to 18 antimicrobials
according to NCClS recommendations. ESBls were detected by the
double-disk synergy test (DDST).
Results: Fifty-four E. coli (10.7%) and 30 K. pneumoniae (32.2%) strains
were producing ESBLs. Of ESBls producers, 65% were recovered at
surgery clinics. Against E. coli and K. pneumoniae strains IPM, TZP and
CIP were the most active agents with 100%. 70-56% and 70%-57%
susceptible strains respectively.
Conclusions: The DDST method is useful and necessary since ESBls
producers often have low-level resistance to third-generation cephalospor-
ins. Moreover, Imipenem, Piperacillin/Tazobaetam and Ciprofloxacin
showed good in vitro activity against ESBls producing strains of E. coli
and K. pneumoniae.
IWeP60 lin vitro activity of piperacillin alone and combined
with sulbactam or tazobactam against hospitakterived
pathogens
M. Seewald
Laborzentrum, Berlin, Germany
Objectives: To evaluate the in vitro activity of piperacillin (PIP) in combi-
nation with sulbaetam (S). a {3-lactamase inhibitor which is available as single
agent, as compared with the fixed combination piperacillin/tazobaetam
(PIP/T) in hospital-derived pathogens.
Methods: From May to December 1999, in-vitro susceptibilities of 1609
Gram-negative and 1702 Gram-positive strains were determined using the
microdilution method according to DIN 58940.
Results: The following table shows the percentages ofstrains (most frequent
species) found to be fully susceptible to piperacillin + /- inhibitors,
ceftazidime (CTAZ), imipenem (IMIP) and ciprofloxacin (CIPX).
% Susceptible N PIP PIP/S PIPIT CTAZ IMIP CIPX
E. coli 821 70 94 97 99 100 97
Enterobact~r spp. 103 77 79 80 82 99 98
Kltbsitlla spp. 138 9 82 82 98 100 97
ProteuJ mirabilis 172 92 98 98 99 100 98
P. aeruginosa 184 90 90 92 95 90 96
Bacteroides spp. 50 95 100 100 100
S. aur..... 521 16 98 98 80 98 92
Coag.-""g. staph. 561 23 83 83 28 82 75
EntnOlollUS spp. 509 98 98 98 0 98 3
fJ-htm. strtpt. 75 100 100 100 100 100 7
Condusion: The combination of piperacillin with the single-agent {3-
lactamase inhibitor sulbactam is as active as the fixed combination piper-
acillin/tazobaetam and compares very favourably to other broad-spectrum
antibiotics.
IWeP61 ISulbactam. tazobactam, c1awlanic acid: Activity of
combinations with ,B-lactams against aerobes and anaerobes
J. Focht
Bioscielllia, Institute for Laboratory Medicine, Microbiological Department,
Moers. Germany
Objectives: To compare the activity of sulbactam. a {3-lactamase inhibitor
available as single agent, in combination with different penicillins and
cephalosporins vs. fixed {3-lactam/inhibitor combinations vs. other broad-
spectrum antibiotics in a large sample of representative and clinically
important hospital-derived pathogens.
Methods: In a retrospective analysis (1996-1998). in-vitro activities of
piperacillin (PIPC), mezlocillin (MEZC), ampicillin (AMPC), amoxycillin
(AMOX), cefotaxime (CTAX) and ceftriaxone (CTRX) alone and in
combination with sulbactam (SU), tazobactam (TZ) or c1avulanic acid
(CA) were investigated. Using the microdilution method (DIN 58940),
resistance rates of 37,517 isolates were determined (18,200 Gram-negative
aerobes. 14,398 Gram-positive aerobes, 4,919 anaerobes; source: Bioscientia,
Institute for laboratory Medicine, Moers).
Results: Combined with penicillins, SU considerably reduced resistance
rates in Gram-negative and Gram-positive aerobes and in anaerobes, and
proved as efficacious as TZ and CA. Among all pathogens tested. the
percentages of resistant strains were 41 for PIPe, 7 for PIPC/SU, 6 for
PIPqTZ, 47 for MEZC. 14 for MEZqSU, 61 for AMPC, 25 for AMPC/
SU and 25 for AMOX/CA. The differences were mainly due to different
activities against Gram-negative aerobes, where the percentages of resistant
strains were 8 for PIPqSU. 21 for MEZC/SU, and 44 for AMPCfSUL.
When combined with CTAX or CTRX, the effect of sulbactam was
markedly less pronounced than combined with penicillins.
Condusions: Combinations ofpenicillins with sulbactam are as active as the
combinations with tazobactam and c1avulanic acid, and are a useful addition
to the antibacterial armamentarium.
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IWeP621 Comparative activity of 3 betalactamase-inhibitors in
combination with ampicillin and piperaclllln against gram-
negative bacteria
H. K. Geiss', A. Schmalreck
'Institute ofHygiene; Heidelberg, Germany; Mack GmbH lIlertissen
Objectives: To evaluate the MIC reduction of Ampicillin (A) and Piper-
acillin (P) combined with either Clavulanic Acid (C), Tazobactam (T) or
Sulbactam (5) in Gram-negative bacteria.
Methods: The MIC of 735 Gram-negative bacteria isolated from blood
cultures comprising 20 different species was determined in microtiter plates
(Merlin, Bonn, Germany) with A, AC, AT, AS, P, PC, PT, and PS.
Results: The following figure summarizes the results, exhibiting the best
activity of the T-combinations, which is even more pronounced with
specific species (e.g. E. coli).
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lWeP~ The Alexander Project 1998: Comparative activity of
I3-lactam and macrolide antimicrobials against S. pneumoniae
using pharmacodynamic (PD) breakpoints (BP)
M. R.Jacobs', P. C. Appelbaum2, D. Felmingham3
The Alexander Project Croup; 'Case Western Reserve University, Cleveland,
OH; 2Hershey Medical Centre, Hershey, PA, United States; JGR Micro Ltd.,
London, United Killgdom
Objectives: This study used PD breakpoints, defined as the MIC corre-
sponding with serum concentration present for 40-50% of the dosing
interval, to investigate the antimicrobial susceptibility of S. pneumoniae for
sdected oral tinle-dependent agents and dosing regimen!ll._
Methods: Using PD BP set by mean serum-tirne profiles obtained from the
literature, susceptibility was calculated for 4012 Alexander Project pneu-
mococci from community LRTI collected during 1998.
Results: MIC90 (mg/L) and percentage of strains susceptible at dosing
regimens shown were:
Antimicrobial Dose (mg) PDBP MIC90 %susceptible
Amox/clav 500 tid 2 2 94.4
Amox/clav 875 bid 2 2 94.4
Cefuroxime axetil 500 bid \ 8 74.\
Cefuroxime axetil 250 bid 0.5 8 72.0
Cefaclor 250 tid 0.5 > 128 21.0
Cefaclor 500 tid 1 > 128 58.5
Erythromycin 250 tid/qid 0.5 > 32 71.8
Erythromycin 500 tid/qid 1 > 32 72.1
Clarithromycin 250 bid 0.25 > 32 71.9
Clarithromycin 500 bid I > 32 72.1
Condusion: The most active oral ~lactam against S. pneumol/iae was
amoxycillin ± c1avulanate, at 500 mg tid or 875 mg bid. PD breakpoints
provide a useful dosing regimen-based tool for comparing agents and
optimising empirical antimicrobial therapy.
[WeP64J The Alexander Project 1998: I3-lactamase production
In H. inftuenzae
D. Felmingham" P. C. Appelbaum' , M. R.Jacobs3
The Altxander Project Group; 'GR Micro Ltd., London, United Kingdom;
ZHershey Medical Centre, Hershey, PA; JCase Westtrn Reserve Univer<ity,
Cleveland, OH, UI/ited Stales
Objectives: Continued worldwide surveillance of ~lactamase production
amongst community-acquired R TI pathogens.
Methods: Susceptibility testing was performed using broth microdilution
(NCCLS) methodology.
Results: In 1998, 4187 isolates of H. injluenzae were collected. The overall
prevalence of~Iactamaseproduction was 20.2%. The proportion ofisolates
producing ~laetamaseby country is shown below:
Country No. %iM-+ Country No. %L+
Czech
Kenya 21 0.0 Rep. 98 14.3
Italy 100 2.0 Belgium % 15.6
Austria 153 3.9 Greece 50 16.0
Poland 273 4.4 Eire 111 17.1
South Africa 70 5.7 UK 100 18.0
Netherlands 141 6.4 Mexico 631 9.0
Germany 193 6.7 Singapore 100 21.0
Saudi
Slovak Rep. 99 8.1 Arabia 79 21.5
Japan 246 9.8 France 158 22.2
Switzerland 105 10.5 Israel 4-4 22.7
Hong
Portugal 213 11.7 Kong 222 29.3
Brazil 83 13.3 USA 1370 35.6
The prevalence of ~Iactamase-negativeampicillin-resistant (breakpoint
~ 4 mg/L) isolates remained low at 0.5% (21 isolates).
Conclusion: Although the overall prevalence of~lactamaseproduction in
H. injluenzae seems stable for each country, there are significant variations
between countries in the antimicrobial susceptibility of this pathogen.
IWeP6S1 The Alexander Project 1998: Penicillin resistance in S.
pneumoniae
M. R. Jacobs·, P. C. Appelbaum2, D. Felmingham3
The Alexander Project Group; 'Case Westem Reserve University, Cleveland,
OH; 2Hershty Medical Centre, Hershey, PA, United States; JGR Micro W.,
London, United Kingdom
Objectives: Continued worldwide surveillance of penicillin susceptibility
amongst isolates of S. pneumoniae from community-acquired R TI.
Methods: Antimicrobial susceptibility testing was performed on 4012
isolates of S. pneumoniae using standard microbroth dilution (NCeLS)
merhods.
Results: Penicillin susceptibility for 1998 is shown by region below:
Pen-I +
Region N Pen-S Pen-I Pen-R Pen-R
Western Europe 1437 80.6% 8.0% 11.4% 19.4%
Eastern Europe 315 81.9% 9.2% 8.9% 18.1%
North America 1456 54.1% 14.9% 31.0% 45.9%
South America 181 64.6% 22.1% 13.3% 35.4%
Middle East 105 53.3% 21.9% 24.8% 46.7%
Africa 121 65.3% 28.1% 6.6% 34.7%
Far Ust 397 37.3% 17.6% 45.1% 62.7%
Combined data 4012 64.9% 13.2% 22.0% 35.1%
Conclusions: Overall penicillin non-susceptibility in 1998 was 35.1 %
(13.1 % pen-I. 22% pen-R); ten countries exceeded 40%: Israel (41.8%),
South Africa (43.9%), USA (45.9%), Slovak Rep. (51.4%), France (53.3%),
Mexico (56.3%), Singapore (59%),Japan (61.6%), Hong Kong (72.3%) and
Saudi Arabia (78.6%). Penicillin resistance continues to evolve in the
countries participating in The Alexander Project.
IWeP66! Alexander project 1998: Comparative in vitro activity
of 20 antimicrobials against community-acquired LRTI isolates
P. Appelbaum!, O. Felmingham2, M. R.Jacobs3
The A/exatlder Project Croup; 'Hershey Medical Centre, Hershey, PA, United
States; 2CR Micro Ltd., London, United Kingdom; JCase Western Reserve
University, Cleve/and, OH, United States
Objectives; Continued worldwide surveillance of antimicrobial suscept-
ibility of LRTI pathogens.
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Methods: Collection of LRTI pathogens from 24 countries and suscept-
ibility testing of 20 antimicrobials by standard microbroth dilution
(NCCLS).
Results: Results for 1998 provided data for 8982 LRTI isolates, including
4012 S. pneumoniae, 4187 H. injluenzae, 663 M. cata"halis and 120 S.
pyogenes. MIC90s (mg/L) for selected antimicrobials in 1998 were:
Agent s. pnnlmOnidt H. influenza. M. catarrhalis S. pyogenes
Penicillin 2 O.ot
Ampicillin 4 > 16 16 0.03
Amoxycillin 2 > 16 16 0.03
Amoxjclav 2 1 0.25 0.03
Cefuroxime 8 2 2 0.01
Clarithromyein > 32 16 0.5 64
Azithromyein > 32 2 0.06 64
Ofloxacin 2 0.12 0.12 2
Overall peniciIIin non-susceptibility in S. pneumoniae was 35.2% in 1998
(13.2% pen-I, 22% pen-R). ,8-Lactamase production was 20.2% in H.
injluenzae and 93.6% in M. cata"halis. All 1998 S. pyogenes isolates were
susceptible to penicillin and 71.7% to the macrolides.
ConclusIons: Based on pharmacodynamic breakpoints, the most active oral
p-Iactam tested in 1998 against all pathogens was amoxyciIIin/c1avulanate,
and ofloxacin, representing the f1uoroquinolones, was the most active non-
p-Iactam.
IWeP67[ Resistance profile of Enterobacteriaceae showing
synergy between davulanate and ,B-laetams: An Italian survey
T. Spanul , F. Luzzar02 , M. PeriIli3 , A. Toniol02, G. Arnicosante3 , G.
Fadda l
The Italian ES,8L Study Group (G. Bonfiglio, G. Fortina, G. Gesu, A.
Goglio, E. Magliano, F. Menichetli, G. Miragliotta, F. Nicoletti, G. Nicolelli,
G. Ortisi, R. Vaiani); 'Catholic University, Rome; 2Univ. of Insubria,
Varese; JUniversity ofL'Aquila, Italy
Objectives: infections due to ceftazidime-resistant, extended-spectrum P-
lactamase (ES/1L)-positive Enterobaaeriaeeae are increasing (Chanal, 1996;
Coudron, 1997; Wiener, 1999). We performed a nationwide survey in 1999
to assess both the prevalence and the resistance profile of the above isolates.
Methods: 8,015 consecutive, non-duplicated Enterobacteriaceae isolates were
obtained from ten Laboratories and screened for resistance to expanded-
spectrum p-lactams. Five hundred and nine multiresistant isolates were
suspected to produce an ES/1L enzyme since showed a synergic effect of
c1avulanate with selected ,B-Iactams (ceftazidime, aztreonam, cefotaxime,
ceftriaxone). MIC values of each isolate (E-test) were obtained for 13
antimicrobials (widely used p-Iactams, gentamicin, arnikacin and ciproflox-
acin) and combinations with ,B-Iactamase inhibitors (amoxycillin-clavulanic
acid, ampicillin-sulbactam, piperaciIIin-tazobactam, cefotaxime-clavuIa-
nate, ceftazidime-clavulanate).
Results: Out of 509 ES/1L-positive organisms (prevalence 6.3%) K. pneu-
moniae and P. mirabilis isolates were the majority (63%) of strains. Suscept-
ibility to imipenem was 100%, while that to other drugs varied: cefoxitin
(77.6%), amikacin (74.7%), gentamicin (56.6%), ciprofloxacin (57.4%),
piperacillin-tazobaetam (90.6%), amoxyciIIin-clavulanic cid (84.1 %), ampi-
cillin-sulbulbactam. (60.2%).
Conclusions: multiresistant Enterobacteriaceae (more often ES/1L-positive)
are well represented in Italian clinical settings, including ICUs. p-lactamase
inhibitors appear to recover the activity of,B-Iactarns in up to 90% of cases.
Though it is difficult in some species to differentiate ES!JL-positive from
cephalosporinase-positive isolates, therapeutic options for multiresistant
Enterobacteriaceae remain limited in both cases. Combinations such as
piperacillin-tazobactam appear to represent an effective choice.
IWeP6SIDevelopment of resistance to ceftazidime and
cefepime in Enterobacter cloacae
S. Saidian, H. Hanberger, M. Nilsson, L. E. Nilsson
University Hospital, Linkiiping, Swtden
Objectives: To study the risk of development of cephalosporin resistance
among susceptible strains of Enterobacter cloacat during exposure to ceftazi-
dime and cefepime, respectively.
Methods: High inocula (107 CFU/ml) of one reference strain (ATCC
13047) and 10 clinical isolates of E. cloacae, susceptible to ceftazidime and
cefepime, were exposed to 0.04-64 mgfl ceftazidime and cefepime. respec-
tively, during 24 h in broth at 37°C. MIC was determined with Etest (AB
Biodisk) in each exposed culrure and in an unexposed culture ofeach strain.
Results: The MICs ofceftazidime and cefepime for the 11 tested strains ofE.
cloacae ranged between 0.25-1.0 mg/l and 0.03-0.125 mg/I, respectively.
Development ofresistance to ceftazidime after 24 h exposure to ceftazidime
in broth was seen for all strains at concentrations ~ 0.5 x MIC. In these
culrures the ceftazidime MICs increased 120 to ~1024 times and the
cefepime MICs increased 8 to 64 times. A similar increase in MIC was
seen after exposure to 0.125 to 4 x MIC ofcefepime. However, there was no
development of resistance in high cefepime concentrations (> 4 x MIC).
Conclusion: High concentrations (> 4 x MIC) of cefepime prevent
development cephalosporin resistance.
IWeP69IExtended-spectrum-&-Iaetamase producing in
outpatients
M. A. Orellana, M. Aramendi, G. Galera, C. Moyano, M. A. Amerigo
Ambulatorio Hermanos Miralles, Area11, Madrid, Spain
Objetives: To srudy the incidence ofE. Coli, K. Pneumoniae and K. Oxytoca
strains producing ESBLs in isolates from outpatients and to evalue the
susceptibility of this strains to aminoglycoside antibiotics, quinolones and T I
S.
Methods: During the year 1999,39 strains producing ESBLs were isolated
from diferents samples. The strains were identified using the authomatic
system WaIkaway-MicroScan (Dade-Berhing). This system has a sofware
that identifie this strains, using the criteria: Ceftazidime and/or Cefotaxime 2
uglml., Aztreonam 2 ug/mI. and decrease ofCMI for AmoxyciIIin/CIavu-
lanic.Acid.
Results: The strains isolated were: 35 E. Coli and 4 Kltbsitllas (3 K.
Pneumoniae and t K. Oxytoca).
The samples where this strains were isolates are: 27 uroculture, 3 injury
exudates, 8 vaginal exudates and 1 uretral exudate.
The r~'Sistance to Aminoglycosides were: Amikacin (Ak) 48.7%. Genta-
micin (Gm) 58.9%, Tobramycin (To) 53.8%. The resistance to Ciproflox-
acin (Cip) were: 20.5% and TIS: 28.2%.
The resistance ofstrains no producing ESBLs during the same year to this
antibiotics were: Ak 1%, To 7%, Gm 9%, Cip 20% and T/S 31 %.
Conclusions: This strains are isolated in outpatients frecuendy. These strains
are more resistents to Aminoglycosides than strains no producing ESBLs.
The<e <trains are the <arne resistant to CiproAoxacin and TIS.
IWeP70IComparative determination of the minimal
inhibitory concentration of piperacillinlsulbaetam versus
piperacillin/tazobactam against common nosocomial pathogens
isolated from intensive care patients in Gennany
U. Frank, D.Jonas, E. Schmidt-EisenIohr, F. Daschner
Institute ofEnvironmental Medicine and Hospital Epidemiology, Freiburg,
Germany University Hospital
Objectives: To investigate the antimicrobial activity of piperacillin/tazo-
bactam versus piperaciIIin/sulbactam against nosocomial pathogens isolated
from intensive care patients.
Methods: During a 12-month period (Sept. 97-Sept. 98), 19 laboratories
throughout Germany supplied gram-positive and gram-negative isolates
from ICU patients with nosocomial infection. MethiciIIin-susceptible Sta-
phylococcus aureus (MSSA, n = 101), coagulase-negative staphylococci
(CNS, n = 50), Enterococcusfaecium (EFCM, n = 51). Escherichia coli (n =
51), Enterobacter cloacae (n = 53), Klebsiella pntumoniae (n = 52), Proteus
vulgaris (n = 51), Morganella morganii (n = 53), Pseudomonas aeruginosa (n =
102) and AcinetobaCler baumannii (n = 51) were tested for their susceptibility
to piperacillin alone and in combination with either tazobactam or sulbac-
tam. Susceptibilities were determined using the micronaut system (break-
point procedure).
Results: For gram-positive bacteria (MSSA, CNS, EFCM), antimicrobial
susceptibilities to the two piperacillinfbetalactamase-inhibitor combinations
were almost identical. For gram-negative bacteria. pathogen-specific differ-
ences in antimicrobial activity were noticed between sulbaetam and tazo-
bactam. The piperaciIIin/tazobactam combination exhibited greater activity
against E. coli, P. vulgaris and M. morganii than piperacillin/sulbactam. For E.
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cloacae and K. pneumoniae, however, the piperacillin/sulbactam combination
proved superior. Piperacillin was equally effective against Pseudomonas
aeruginosa with and without betalactamase-inhibitor. The piperacillin/sul-
bactam combination exhibited best antimicrobial activity against A. bau-
mannii.
COnduslons: Common gram-negative microorganisms exhibit varying
degrees of susceptibility to a combination of piperacillin and wobactam
or sulhactam. These fmdings might prove important for appropriate choice
of antibiotic therapy.
[WeP~1J Molecular characterization of a new Class BMetallo-
I3lactamase from Senafia fonticola
M.J. Saavedra l , A. Correia2,J. C. Sousa3,J. RodriguesJ, L. Peixe3
'UTAD- Dep. de Higiflle e Sanidade; 2Cetltro de Biologia Celular- UA; JFac.
Farmacia UP-Lab. Microb., Porto, Portugal
Objectives: To determine the sequence ofa new carbapenemase conferring
resistance to imipenem in a Serratia fonticola strain (UTA054) isolated from
drinking water.
Methods and: Results: The MICs (determined by Etest) ofScrratiajonticola
isolate revealed susceptibility to oxyiminocephalosporins (0.125 J1.g/ml-2
J1.g/ml) and aztreonam (0.75 J1.g/ml). A carbapenemase activity was demon-
strated in crude sonicates of cell suspensions by a bioassay plate. The /3-
lactamase determinant was i.solate from a genomic library of UTAOS4,
constructed in an Escherichia coli plasmid vector, by screening for clones with
reduced susceptibility to imipenem. Sequencing of the cloned gene, sjhI,
revealed that the open reading frame extends for 705 bp and encodes a
protein of 234 amino acids with a predicted pi of 5.89. The sjhI ORF
sequence shows 56% identity to cphA (Aeromomas hydrophila) and 55%
identity to imiS (Aeromonas veronii bv. sobria), members of subclass Bb.
Condusions: The new Sfhl enzyme, responsible for imipenem resistance in
S. fonticola UTA054, appears to be related to the class B /3-lactamase.
IWeP72IPenicillin resistant Streptococcus pneumoniae in
Kuwait
E. M. Mokaddas l.2, S. Wilson l , S. C. Sanyal2
'Faculty ofMedicine; 2Ibn Sina Hospital, Stifat, Kuwait
Objectives: To ascertain the preponderance of Streptococcus pneumoniae,
either resistant or intermediate resistant to penicillin, other /3-lactams and
non ,B-Iactam antimicrobials in different hospitals in Kuwait.
Methods: One hundred fresh isolates of S. pneumoniae from as many
patients suffering from different clinical conditions were collected from all
the hospitals in Kuwait. Optochin sensitivity and bile solubility tests
reconfirmed these. Susceptibility testing to penicillin, cefuroxime, ceftriax-
one, cefotaxime, imipenem, erythromycin, chloramphenicol, vancomycin
and ciprofloxacin was done using E-test strips and to oxacillin, tetracycline
and trimethoprim by disk diffusion technique.
Results: Full and intermediate resistance to penicillin was observed in 2%
and 50% of the isolates respectively. Full resistance to second and third
generation cephalosporins ranged from 5% to 7%, however, intermediate
resistance to these antibiotics varied between 10% and 25%. The rate ofS.
pneumoniae resistant to chloramphenicol, erythromycin, tetracycline and
trimethoprim were between 8% and 40% and intermediate resistant
between 2% and 16% while only 1% showed resistance to ciprofloxacin
and none to vancomycin.
COndusions: These data thus indicate that full resistance ofS. pneumoniae to
penicillin and other 13-lactams is low in Kuwait, but a large proportion ofthe
hospital isolates are intermediate resistant making the optimal choice of
therapy difficult in serious infections. Moreover, multidrug resistance in S.
pneumoniae is also common.
IWeP73ISusceptibility patterns and extended spectrum beta-
laetamase (ESBL) production of salmonella strains
M. A. Mehr i.. H. Bahar, Z. GUlay, N. Yulug
Dokuz EyliiI Univ., School of Medicine, Dept. ofMicrobiology, izmir, Turkey
Objective: To investigate the in vitro antibiotic susceptibility of and ESBL
production in Salmonella isolates.
Methods: A total of71 salmonella isolates which consisted of46 nosocomial
and 25 sporadic strains. were taken into the study. S. typhimurium accounted
for 95.7% of the strains isolated from two nosocomial outbreaks. Among
sporadic isolates the most common serotype was S. typhi (44%). Antibiotic
susceptibilities were assessed by the NCClS disk diffusion method. ESBl
production was detected by double disk synergy test.
Results: All ofthe isolates were resistant to at least two antimicrobial agents.
Multiple antibiotic resistance rate was highest for S.typhimurium and 85% of
the isolates belonging to this serotype were resistant to at least eight agents.
Among S. typhi isolates 27% possessed the same feature. The overall
resist.mce rates to several antibacterials including ampicillin, chlorampheni-
col, trimethoprim-sulfamethoxazole, amoxycillin-clavulanic acid, cefotax-
ime and ceftazidime were, 90%, 72%, 52%, 68%, 30% and 35%,
respectively. The isolates were universally sensitive to quinolones, imipenem
and cefoxitin. ESBls were detected in 27 (38%) isolates. ESBL production
among strains of two nosocomial outbreaks were 63.6% and 45.8%.
However; in strains that were isolated from sporadic cases ESBL production
rate was 8%. All of the ESBl producers belonged to serorype Typhimur-
ium. The strains possessed 13 different plasmids (1.1 to 210 kb). Ten ofthe 27
ESBL producers transferred this feature to the recipient E. coli in association
with 10, 100 and 210 kb plasmids.
Conclusion: In Izmir, multiple antibiotic resistance is a problem which
limits sucessful antibiotic therapy especially in infections due to S. typhimur'
ium.
IWeP74IAlterations in penicillin binding protein 5 (PBPS) in
imipenem sensitive and resistant strains of Enterococcus
faecium
N. E. Amin, C. lundberg, S.Jalal, K.Jalakas-Pomull, B. Wretlind
Div Clin Bact, Huddinge, Sweden University Hosp, Karolinska Institute
Objective: To determine alterations in penicillin binding protein 5 in
Enterococcus faecium strains, resistant or sensitive to imipenem.
Methods: Three imipenem resistant, ampicillin sensitive E. faecium clinical
isolates with MICs 0.25, 0.75, and 1.0 mg/ml for ampicillin and> 32 mg/ml
for imipenem, were examined for alterations in penicillin binding protein 5
(PBP5). E. faecium ATCC 19434 (MICs 0.064 for ampicillin, 0.75 mg/ml
for imipenem), was included as a reference. PCR was performed using
primers from E. faecium 9439. The 854 bp PCR fragments were analyzed by
direct DNA sequencing.
Results: Four amino acid substitutions were observed in the three clinical
strains in the penicillin-binding domain (amino acids 386-627). Alanine at
position 358 in the reference strain was changed to threonine or serine (GCT
to ACT or TCn in the resistant strains, lys 491 to Asp, Thr 494 to Ala
(ACA to GCA) and Asp 520 to Glu (GAT to GAG). The amino acid
sequence of the resistant strains showed homologies of99, 98, and 97% with
plasmid-borne E. hirae PBP3r, E. faecium ATCC 19434 PBP5, and PBP5 of
the amipicillin resistant strain 0366, respectively.
COndusions: Changes in E. faecium susceptibility to imipenem were
associated with alterations in PBP5, and PBP5 of the ampicillin sensitive,
imipenem resistant strains differed by only one amino acid from PBP3r from
E. hirae.
IWeP7S1 Comparison of the system VITEK results for the
methicillin resistance with the detection of mecA gene in
Staphylococcus spp. clinical isolates
G. Vrionil •2, E. Papoutsakil , P. Matsiota-Bernard2
'Microbiology Laboratory, KAT Hospital, Athens; 2Microbiology Department,
Medical School, University ofAthens, Greece
Objectives: Accurate and rapid detection of methicillin-resistant staphylo-
cocci is a constant challenge for clinical laboratories, particularly due to the
heterogenous resistance ofmany strains. This study compared the results for
the methicillin resistance from Vitek with the detection of mecA gene in
Staphylococcus aI/reus (SA) and Coagulase Negative Staphylococcus spp
(CNS).
Methods: Eighty clinical staphylococci isolates (40 SA and 40 CNS),
isolated from January 1999 to September 1999, included in the study.
Identification and susceptibility testing were performed on Vitek automated
system (bioMerieux). These strains were genotypically characterized for the
mecA gene presence by PCR method using the mecAl
[5'GTAGAAATGACTGAACGTCCGATAAI and the mecA2
[5'CCAATTCCACATTGTTTCGGTCTAAI primers. Oxacillin agar
screen method (OX) was performed in the case of discrepant results.
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Results: The agreement for SA was 92.5% and for CNS 87.5%. Mean time
of susceptibility test on Vitek was 8 hours for SA and 11.8 hour.; for CNS.
Staphylococcus au"u, Coagulase Negative Staphyloco[{llS
Methicillin VITEK mecA Methicillin VITEK mecA
-----
IWeP77! Detection of extended spectrum beta-Iactarnase
(ESBL) - Producing strains with ETest ESBL strip
IWeP76IDevelopment of resistance during carbapenem
treatment
IWeP79IExtended spectrum ,8-Iactamases (ESj1Ls) In clinical
isolates of Escherichia coli and Klebsiella pneumonlae from
patients with eatheteNSSOCiated urinary tract Infection (CAUTI)
A. Hernandez l , A.r Rodriguezl , B. BeltranZ, H. Tortoler03,]. Rieral , I.
Bell04, D. Vasquez
tVargas Medical School; 'Urology; JMicrobiology and Inftctious Diseases;
4Surgery II; Vargas Hospital, Caracas, Venezuela
Objectives: Study the incidence ofESj1Ls in clinical isolates ofEscherichia coli
and Klebsiella pneumoniae from patients with catheter-associated urinary tract
infection (CAUTI) isolated in 1999.
Methods: Fourteen isolates ofE. coli and 7 Klebsiella pneumoniae were tested
for production of ESm. by double-disk test performed with ampicillin,
amoxycillin, amoxycillin-clavulante, ampicillin-sulbactam, and piperacil-
lin-tazobactam disks.
Results: We observed ESm. production in 50% E. coli (P < 0.05) and
14.29% K. pneumoniae. Non-ESm. production was observed in 35.71% E.
coli and 85.71 % K. pneumoniae.
Conduslons: These results suggest a contrasting data reported in literature
about percentage of E. coli and K. pneumottiae with production of ES,8Ls
isolated from CAUTI, limiting use of J1-lactams in this setting.
Objectives: The wide spectrum ofactivity ofmeropenem and its suitability
as monotherapy for infections with many resistant organisms has been
documented. As a carbapenem it is reported to be more stable, in solution,
than imipenem. Meropcnem could therefore be a useful agent for outpatient
intravenous therapy. The objective of this study was to determine the
stability of meropenem, over time, in differing concentrations, diluents
and temperatures.
Methods: Meropenem solutions were prepared at 30 giL and 60 gIL in 3
diluents (normal saline, 5% dextrose & sterile water). They were maintained
at -20°C, +4°C, + 20°C and + 35°C for up to 7 days. Aliquots were
removed at set times and the residual antibacterial activity was assayed by
bioassay using B. subtilis ATCC 8236 on Columbia agar and confirmed using
direct quantitation of meropenem by HPLC.
Results: Both techniques gave similar results although HPLC was exqui-
sitely accurate (RZ > 0.999 on standard curve). The higher concentration
was significantly less stable. Solutions in sterile water and normal saline were
more stable than those in 5% dextrose. Stability was strongly temperature
dependent with minimal losses at -20°C. At higher temperatures the time to
loss of 20% antibiotic activity was approximately 106, 24 and 9.5 hours
(+4°, +20° & +35°q.
Condusions: We feel pre mixed meropenem, at a concentration of30 mg/L
in normal saline or sterile water, is sufficiently stable to be stored for up to 72
hours at + 4°C (home refrigerator). It could then be administered via
programmable pump at 8 hourly intervals resulting in a maximum admin-
istration time of 16 hours. The losses of antibiotic activity from such a
strategy should not compromise effective therapy. The issue of the possible
toxicity (sensitisation) from degradation products remains to be explored.
IWeP80IAntimicrobial drug susceptibilty and Extendend-
Spectrum Beta-Laetarnase (ESBL) production of Salmonelill spp
and Shigella spp isolated from community acquired infections in
Turkey
D. Kilic l , S. Tekin l , G. Tuncerl , N. Tulek l , L. DoganooZ, A. Wilke3
Departme", ofClinical MicrobiolOfY and Infectious Diseases of'Ankara
Training and Research Hospital; Ankara, Turkey University School of
Medicine; 'GA T A Department ofClinical Microbiology and Microbiology
In this study, we evaluated the antimicrobial susceptibility ofSalmottella and
Shigella strains isolated from community aquired infections. We also
investigated the ESBL production of these isolates. 117 Shigella spp and 84
Salmonella spp were included in this study. Antimicrobial susceptibility of
strains were tested by disc diffusion methods according to the NCCLS's
criteria. ESBL production was determined by double disc synergy and
inhibitor-potentiated disc-diffusion tests. The results were summarised in
able.
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30
Sensitive 15
Resistant 25
12
28
15
25
Sensitive
Resistant
With the OX method: 1) for the three SA strains Vitek (S)/mecA (+), one
was MRSA and 2) for the five CNS strains Vitek (S)/mecA (+), two were
MR-CNS.
Conclusions: Even thought the sensitivity was better for SA, Vitek turned
out to be effective and accurate automated system for the rapid detection of
methicillin-resistant staphylococci.
J. Meszaros l , G. Michalak l , M. Dabkowkaz, A. Sawicka l , A. Rokosz'
Department ofGeneral & Transplantation Surgery; 'Medical Univrrsity of
Warsaw & Children's Memorial Hospital, Warsaw, Poland
Carbapenems - imipenem/cilastatin or meropenem - were used in the
treatment of 320 patients with severe surgical sepsis. Pathogens isolated on
the beginning of therapy - gram-negatives, anaerobes, staphylococci and
streptococci - were sensitive (95%) to both drugs. Cultures were performed,
depending on clinical diseases, in 1-3 weeks of therapy. Among 133 clinical
isolates there were two resistant groups: 1) bacterial strains primary sensitive
to carbapenems that acquired resistance during treatment and 2) strains
naturally resistant to carbapenems isolated in superinfection during therapy.
In the first group 23% ofgram-negatives were resistant to both drugs (MIC
16-64 ug/ml), including P. aeruginosa, A. anitratum, S. marcescellS, E. cloacae
and 26% of meticillin-resistant staphylococci. The second group (51 %)
included S. maltophilia. E.faecalis, C. difficile and Candida albicans. The results
confirmed that imipenem and meropenem therapy implies increased risk of
the emergence ofresistance, determined by selection ofresistant populations
of microbes during treatment and superinfections with microbes, naturally
resistant to carbapenems. The selection of P. a"uginosa resistant to carbape-
nems, the most active drugs against these pathogens, was closely related to
clinical disease and was higher in difficult to treat, severe infection with
progressive illness.
R. Vacheva, E. Savovq
MMM, Sofia, Bulgaria
Objectives: To study the prevalence of ESBLs in clinical isolates (760 of
Enterobacteriaceae) from ICU and compares two methods of detection.
Methods: The microorganisms were investigated by the Mini API system
(Bio Merieux, France). The double-disk (DD) test and E test ESBL (AB
Bidisk, Sweden) were used. E test ESBL strip carry two gradients-ceftazi-
dime (TZ) and ceftazidime with c1avulanic acid (TZL). An MIC ratio TZI
TZL > 4 is indicative ofESBL( +). The MICs ofgentamicin, ciprofloxacin,
amoxicillin/clavulanic acid, ceftazidime, ceftriaxone, cefepime, eefotaxime,
aztreonam were studied by E-test (AB Biodisk, Sweden).
Results: The 86 ESBL-producing strains were recovered from endotracheal
aspirate (36), wounds (23), urine (14), blood (6), etc. (7). In 6 cases DD was
negative, while E-test - positive. ESBL producers caused serious complicated
infection in 23 patients and failure ofinitial antibiotic treatment in ventilated
patients. Klebsiella pneumoniae 63% and Enterobacter cloacae 21 % were
prominent among all ESBL( +) strains.
Conclusions: During the studied period (2 years) 11.3% ofgramm negative
isolates from ICU produced ESBLs. DD test is sufficient for ESBL screening.
Our results confirm the need of sensitive, reliable tests as E-test ESBL in the
defection of ESBL-producing strains.
IWeP78! Stability of meropenem in Intravenous solutions
C. J. Fernandes, G. Kotsiou, L. A. Fernandes, R. C. Pritchard
Microbiology Department, PaLMS, Royal North Shore Hospital, St Leonards,
NSW, Australia
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Table: The antimicrobial susceptibilty of Salmonella and Shigella strains (%).
Nontyphi S.lmontll.
S.lmontll. typhi Shigtll.
(n = 63) (n = 21) (n = 117)
Ampicillin 65 90 68
Co-trimox<lZole 92 95 56
Chloramphenicole 78 95 77
Ciprofloxadn 100 100 100
Ceftriaxone 94 100 100
ESBL production was demostrated in four Salmonella typhimurium strains
and these strains were susceptible to only flouroqinolones and irnipenem but
resistant to other tested antimicrobials. As a conclusion, ciprofloxacin,
ceftriaxonc may be used in emphiric treatment of Salmondla and Shigella
infections if culture and antinnicrobial susceptibility testing could not be
done. On the other hand, this is the first report of ESBL producing
Salmonella strains isolated from community aquired infections in our
country.
IWeP81I Which Is the appropriate technique to asses the
susceptibility of Staphylococcus aureus in dinicallaboratory7
(Beta-Iactams antibiotics)
C. I. Sasca, N. Sasca, V. Laza-Stanca, D. Tifrea, A. Slavcovici, D.
Carstina, F. Sasca
University ofMediei"e "Iuliu Hatiebanu", Cluj-Napoca, Romania
Objectives: To asses the appropriate technique to test the methicillin
resistance of staphylococci in clinical laboratory.
Methods: The susceptibility of 60 Staphylococcus aureus (SA) and 50
coagulase-negative staphylococci (CNS) strains belonging to 8 species
(biochemical identification by API-system Merieux) was tested in Muel-
ler-Hinton (MH) gar without or with 2% NaCI by disk diffUsion, agar
dilution and E-test against oxaciIlin-l and 5 p.g disks, 2, 4 and 16 mg/L
dilution in MH-agar.
Results: 19/60 SA and 23/50 CNS isolates grow on the Oxa 16 mg/LNaCI
MH but only 15/19 SA and 19/23 CNS have an MlC E-test of~16 (with 2/
15 heterogen MRSA), are R in disk diffusion (Oxa 1 p.g on NaCI) and not
susceptible to c1avulanic acid. The other 4/19 SA and 4/23 CNS (MIC E-test
in the range of 0.75-12 mg/L) as well as the 7/60 SA (5 heterogen pattern)
and 8/50 CNS isolates (growing on Oxa 4 mg/L NaC!, E-test 0.19-6) are
Oxa I or S in MH without NaCI. Oxa R. I or S in MH-NaCI and susceptible
to co-amoxiclav.
Conclusion: The isolates with an heterogen methiciIlin resistance pattern
(Oxa R expressed only on MH-NaCI agar), heterogen growth on Oxa 4
mg/L, susceptibility to co-amoxiclav or borderline MlC in E-test need
additional test for the mec-A.
IWeP821 Resistance of Adnetobacter strains to )1-lactam
antibiotics
M. Fleischer, R. Franiczek, M. Stankiewicz, O. Konisiewicz
Dept. of Microbiol., Wroclaw, Poland University ofMedidne
Objectives: The aims of the studies were: to determine the susceptibility of
Adnetobacler strains (n = 336) to j3-laetams, to estimate the ESBL produc-
tion, to compare the plasnnid proftles and determine the transfer ofplasmids
encoding ESBLs from E. coli (n = 13) and K. pneumoniae (n = 15) donors to
Ad"etobacter spp. recipients.
Methods: Identification of Alinetobaeter spp. strains, recovered from clinical
samples, was performed using the ATB system (bioMericux). Susceptibility
to j3-lactams was tested by the disk diffusion method (NeCLS). The double-
disk synergy test (DDT) was used to detected ESBL production. Plasmid
DNA of isolates was obtained by the chloroform-phenol lysis method;
conjugation was carried out by the broth mating method.
Results: The sensitivity to remaining antibiotics differentiated depending on
species. A. baumannji (n = 248) was in majority resistant to all tJlactams; the
isolates were resistanr to cefoxitin (97%), aztrconam (88%); piperaci1lin
(86%), amoxici1lin/c1avulanate (75%), cefotaxime (73%) and ceftazidime
(54%) 21 % of them displayed resistance to innipenem. Plasnnids were
detected in 67% of isolues: large ones were present particularly in multi-
resistant strains. Only 3 ofinvcstigated strains (A. bauma"ni,) expressed ESBL
activity. Attempts to transfer ESBL-mediated resistance from: E. coli and K.
pneumoniae donors to A. baumannii and A. hemolyticus recipients were
unsuccessful.
Condusions: A. baumannii isolates were resistant to majority ofinvestigated
j3-lactams. ESBL-production seems to be the rare phenomenon among
Acinttobacter spp.
IWeP83I In vitro activity of cefprozil compared with other
antlotlcs against respiratory pathogens Isolated in Italy
G. Blandino·, G. Nicoletti!, E. Chelossi2, C. DeLe02, G. C. Schit02
IDtpl. ofMicrobiology, Univ. Calania; Zinst. ofMicrobiology, Univ. Gelloa,
Italy
Objectives: To provide a current evaluation of the antibacterial activity of
cefprozil compared with other j3-lacrams, macrolides and tetracycline on
four major pathogens of community acquired respiratory infections.
Methods: Susceptibility rates of200 Streptococcus pyogenes, 2% Streptococcus
pntllmotliae. 300 Haemophilus injluellzae and 50 Moraxdla catarrhalis recently
isolated from respiratory infections in the laboratories of Microbiology of
Genoa and Catania were assessed by nnicrodilution broth tests in appropriate
media.
Results: According to NCCLS (1999) breakpoints, alI Streptococcus pyogelles,
as expected. were susceptible. On the other hand, a NCCLS-Specific
breakpoint for cefprozil with StreptocolCuS pneumoniae is not available.
However, on the basis of a FDA-suggested breakpoint value ($8 mg/I),
cefprozil demonstrated on S. pneumoniae a better activity than the other
cephalosporins assayed (more than 85% susceptible), except for cefotaxime.
H. injluenzae and M. catarrhalis, both {J-Iactamase positive and negative,
were highly susceptible to cefprozil (H. injluenzae: MIC90 4 mg/l and 98%
susceptible strains; M. catarrhalis: MIC90 2 mg/I and 95% susceptible strains).
Conclusions: Distribution ofMIC levels of cefprozil against S. pyog~s, S.
pneumoniae, H. irifluenzae and M. catarrhalis indicates that this oral cepha-
losporihas a good activity on these respiratory pathogens and may be
considered a useful drug for the therapy of these common infections.
IWeP84! Susceptibility to cefotaxime and other antibiotics
Haemophilus influenzae strains izolated from children during
15-yearperiod(1985-1999)
D. Petreska l , B. Vukovic2, M. Plecas3, M. Mraovic·
'Bacteriology Departmellt, University Children's Hospital, Belgrade;
Lugoremedija - Hoechst Marion Roussel, Zrenjanin; ~LeJe-Polsle4, Belgrade;
Institute- Torlak, Belgrade, Yugoslavia
We studied the susceptibility of 2420 Haemophillus influenzae (HI) strains
isolated from children to cefotaxime and other antibiotics from January 1st,
1985 until July 1st, 1999. The investigation of susceptibility was performed
on chocolate agar with 10% of horse blood and addition of Polyvitex
(bioMerieux) according the recommendation of NCCLS. Quality control
was conducted with H. influenzae strain ATCC 49766. Ampici1lin resistance
was detected by nitrocephin test. Based on the origin and clinical features, all
strains were classified into three groups. The fint was composed of2180 HI
strains from throat and nose swabs; the second was composed of284 mucous
strains isolated from tracheo-bronchial aspirate, sputum, eye, ear and vulva
of children who manifested non-invasive infections, and the third was
composed of56 invasive strains HI type b isolated from blood, CSF, pleural
and joint effusion. Through the studing period the susceptibility ofHI type b
and non-b strains ofthe first and second groups to ampici1lin decreased from
81 to 63%, cefalexin from 32 to 13%, co-trimoxazole from 81 to 52% and
cefaclor from 93 to 83%. The susceptibility to erythromycin ranged from 91
to 85%, chloramphenicol from % to 89%, amoxyci1lin/clavulanic acid from
95 to 93% and cefotaxime from 97 to 95%. The invasive strains HI type b
were highly resistant to multiple drugs and showed susceptibility to
cefotaxime, chlorampenicol and amoxyci1lin/clavulanic acid.
IWeP8S! Comparative bactericidal activity of plperacillin-
tazobactam and piperadllin-sulbactam against piperKillin-
resistant E. coli strains
s. Schubert, U. Ullmann
Dept. ofMed. Microbiology and Virology, Univ. Kid, Germany
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IWeP86ltn vitro activities of SCH 27899 (ziracin. ZIR).
quinupristin/dalfopristin (synercld. SYN). linezolid (UN),
vancornydn (VAN) and other older agents against 255 dinical
isolates of oxadllin resistant Staphylococcus aureus isolated
over four years
D. M. Citron, Y. Y. Kwok, MD Appleman
Los Angeles County + Univ. ofSo. Calif. Med. Ctr., Los Angeles, Calif.,
United States
At 16 mg/l (4 mg/l) the susceptibiliry of the E. coli strains was restored by
piperacillin-tazobactam in 82% (59%) vs. piperacillin-sulbactam in 55%
(34%). Corresponding to this piperaciIlin-tazobaetam yielded MIC90-
values which were 2 dilutions lower than those of piperacillin-sulbactam.
conclusion: Especially for strains producing enzymes ofthe TEM-types the
MICs of penicillins can be reduced by combinations of penicillins plus f3-
lactamase inhibitors. The results of this study confirm that the susceptibiliry
of E. coli-strains against piperacillin is partly restorable by tazobactam and
sulbaetam.
The reconstitutional effect oftazobactam in vitro was much stronger than
that ofsulbactam. The clinical relevance has stilI to be evaluated.
Objectives: To evaluate the activity ofpiperacillin-tazobactam in compar-
ison to piperacillin-sulbaetam against E. coli strains with resistance or
intermediate susceptibiliry against piperacillin.
Methods: A total of 216 non copy strains from patients with different
infectious diagnoses were collected during the period August 1998-August
1999.
The MICs were determined by the microdilution test according to DIN
(German Institution for Standardization) guidelines. The testing was per-
formed in Mueller Hinton broth and an inoculum size of5 x loS cfu/ml. The
microdilution trays were incubated at 36°C for 20 h.
Results: Table: Activity ofpiperacillin-tazobactam and piperacillin-sulbac-
tam against E. coli (n = 216). Cumulative counts at each MIC (mg/I)
P:S/S - Glycopeptides
IWeP89' calibration of fusidic acid disk diuslon in two
countries
B. Olsson-liljequise, S. Koljalg2, I. Karlsson3, G. Kronva1l3
I Sl1DC; JKI, Solna, Sweden; l Ins1 Microbiol, Tartu, Estonia
Objectives: To calibrate the disk diffusion method for fluidic acid and
staphylococci by using single-strain regression analysis (SRA) as a tool for
choosing disk content and establishing interpretive zone breakpoints.
Methods: Routine disk diffusion tests of fluidic acid against staphylococci
are performed according to SRGA with a 50 ug disk in Sweden (breakpoints
available) and according to NCClS with a 10 ug disk in Estoni2 (no
breakpoints available). SRA equation constants were calculated using five
different fusidic acid disk contents (1.5, 5, IS, SO, ISO ug), and these disks
were tested on five separate occasions against quality control strain S. aureus
ATCC 29213 in both countries using their own routine method. Equation
constants were used for calculating zone breakpoints corresponding to
recommended (SRGA) MIC breakpoints (S < = 0.5 mgfL, R > = 1
mgfL)·
Results: Histograms based on routine tests from Karolinska Hospital,
Stockholm and Institute of Microbiology, Tartu, showed clustering of
wild type strains around 41 mm and 30 mm, respectively, reflecting both
different disk contents and different inocula. This was verified by the
calculated SRA constant A, which was quite different in the two labora-
tories, indicating methodological variations. Zone breakpoints calculated
from the equations were validated by comparison with the respective
routine histograms. Breakpoints for the suggested lower disk content 10
ug in Sweden were validated by further routine testing and histogram
analysis.
Conduslons: SRA calibration served as a useful tool to establish test
conditions and interpretive criteria for susceptibility testing of fusidic acid
against staphylococci.
Objectives: Fusidic acid is a potentially important antibiotic for the treat-
ment of C. difliciIe colitis. There are, however, no interpretive zone break-
points issued by reference authorities for this combination. We applied single
strain regression analysis, SRA, to set breakpoints for the individual
laboratory according to recommended MIC-limits for susceptibility.
Methods: Forty strains ofC. difliciIe from colitis cases and reference strain
ATCC 9689 were included and their fusidic acid MIC values determined
using the E-test. Culture of the strains on Columbia blood agar base
supplemented with 5% horse blood was performed in an anaerobic cabinet.
Disk tests followed standardized methodology ofSRGA with modifications
for anaerobic growth. Fusidic acid disks for SRA contained 1.5,5, 15,50 and
150 /-Ig per disk. MIC-limits recommended by SRGA for fusidic acid are S
< = 0.5 J.lg/ml and R = > 1 J.lg/ml.
Results: MIC results indicated possible interpretive errors of rype I. The
absence ofan I category according to SRGA increased error rates. NCClS
fusidic acid MIC limit S < 2.0 mg/l would be more appropriate. SRA
calculations for 40 strains gave a mean curve used to translate MIC limits to
inhibition zones. Using NCClS limits the interpretive zone breakpoints
were S = > 30 mm, R < = 29 mm. No interpretive crrors occurred in disk
test interpretations.
Conclusions: SRA calculations can be used in the individual laboratory to
determine interpretive zone breakpoints for disk testing according to
reference MIC limits.
IWeP90!tn vitro activity of daptomycin against contemporary
Gram-positive dinical isolates from 11 North American Medical
Centers (NAMe)
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IIlockground: Isolation of ORSA with reduced susceptibility to VAN has
been reported worldwide in at least six patients. Several new drugs with
novel mechanisms of activity against ORSA and other Gram-positive
organisms are being developed.
Objectives: To determine if ORSA susceptibility to VAN is decreasing at
our institution and to measure the in vitro activities of new antimicrobial
agents against ORSA.
Method: 255 strains of ORSA cultured from blood, respiratory tract and
wound cultures ofindividual patients at our institution during the last 4 years
were tested by the agar dilution method with an inoculum of 104 cfu/spot
and 24 h incubation at 35° C. ZIR was tested using the Etest. Geometric
mean (GM) MICs were calculated for VAN for strains isolated during each
of the 4 years.
Results: The VAN GM MICs ~g/ml)were as follows: 0.85 in 1996, 0.73 in
1997,0.68 in 1998, and 0.91 in 1999. The MICSO/90 for the other agents were
ZIR 0.75/1, SYN 0.5/0.5, LIN 1./2, rifampin 0.03/2, doxycycline 0.125/1,
TMP/SMX ~ 0.5/9.5/ > 4/76, and trovafloxacin 1.0/4. Most strains were
resistant to clindamycin, gentamicin, and ciprofloxacin.
Conclusions: There was no significant change in VAN MICs during the past
4 years and no homo-resistant strains with VAN MIC > 2 J.lg/ml were
detected, in spite of heavy usage at our institution. ZIR, SYN, and lIN
showed excellent activiry with no resistant strains encountered.
P:S/4 - Fusidic acid
[WeP88IInterpretive zone breakpoints for fusldic add disk
testing of C. dlffidle
E. Holstl , M. Oppenheimerl .2, I. Karlsson2, G. Kronvall2
llnfecr. Dis. & Clin. Microb. Lund; lClin. Microbiol. KI, Stockholm, Sweden
S. Brown, A. Barry, P. Fuchs
Clinical Microbiology Inst., Wilsonville, OR, United States
Objectives: Daptomycin (DAP) is a lipopeptide which. in the presence of
free caldum (Ca + +), is active against Gram-positive bacteria. IJAl' and
vancomycin (VANC) were tested against 2803 clinical isolates gathered
fromNAMC.
Methods: For broth microdilution tests, Mueller-Hinton broth contained
NCClS recommended Ca + + at 25 mg/l and DAP was tested in a second
broth adjusted to SO mg/l Ca + +.
